Steve Case’s Rise of the Rest tour, meant to highlight growing startup ecosystems in five Midwestern cities, will embark on its second leg next week.
Today, the tour announced the finalists for pitch competitions at each of the five stops.... Read more »
Veterans and military spouses from across the country came to Madison, WI, last weekend to take part in Techstars‘ Patriot Boot Camp.
“We’ve been working with a group of approximately thirty military veterans and their spouses to focus on how... Read more »
A federal initiative to ensure that the United States can respond to biological threats at home will be put to the test in response to the Ebola outbreak in West Africa.
A Texas site is preparing to manufacture the experimental Ebola... Read more »
I often say that moving to Detroit was the best decision I made last decade, but there is one thing I left behind that I constantly pine for: My garden.
There’s a beautiful, well-tended community garden in my neighborhood, but good... Read more »
Japan’s Daiichi Sankyo has agreed to acquire San Diego cancer drug developer Ambit Biosciences (NASDAQ: AMBI) for $315 million in cash, with additional milestone payments that could bring the total to $410 million.
The transaction comes just over a year... Read more »
Variety was the word of the weekend at Milwaukee’s first Maker Faire, a gathering for craftspeople of all types and legions of the interested public.
Hundreds of do-it-yourself enthusiasts—from soapmakers to robotics design teams, from clothiers to 3D printers—showed their wares... Read more »
Here are this week’s headlines in North Carolina tech and biotech news:
—Tengion (OTC: TNGN) is looking to use its regenerative medicine technology to secure a possible deal with another company as the Winston-Salem, NC, firm tries to find a... Read more »
One month after his resignation from Epizyme was announced, Jason Rhodes says he’s becoming a partner at Atlas Venture.
At Cambridge, MA-based Epizyme, Rhodes was chief financial officer and president as he helped the firm turn its exploration of epigenetics, a cutting-edge... Read more »
Elan lives on. No, former CEO Kelly Martin isn’t swooping back in his infamous corporate jet. Elan was a high-profile Irish-American biotech that created the multiple sclerosis treatment natalizumab (Tysabri), developed the promising but unsuccessful Alzheimer’s treatment bapineuzumab, and built... Read more »